Home・Akcijų sąrašas・Compugen Ltd

Compugen Ltd

Uždarymo kaina

2.48 1.22

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.44

Max

2.48

Pagrindiniai rodikliai
By Trading Economics
Pajamos	663K -7M
Pardavimai	426K 2.6M
P/E Sektoriaus vid.	6.526 56.432
Pelnas, tenkantis vienai akcijai	-0.07
Pelno marža	-269.254
Darbuotojai	75
EBITDA	665K -7M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+103.25% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-09

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	9.8M 235M
Ankstesnė atidarymo kaina	1.26
Ankstesnė uždarymo kaina	2.48

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-18 23:56; UTC

Packaging Corp of America is trading modestly higher in after-market hours, despite unchanged U.S. industrial production and a decline in manufacturing output.

2026-09-18 23:56; UTC

Below 20-day average, near one-month range in after-market hours.

2026-09-18 23:55; UTC

Extreme Networks Inc is trading modestly higher in after-market hours, reflecting typical performance within its one-month range following Friday's close.

2026-09-18 23:55; UTC

Lumen Technologies Inc is trading modestly higher in after-market hours, rebounding from earlier lows amid a broader trend of five consecutive lower daily closes.

2026-09-18 23:55; UTC

Edison International is trading modestly higher in after-market hours, gradually advancing since Friday's close but remains below its 20-day moving average.

2026-09-18 23:52; UTC

Mosaic Co is trading modestly higher in after-hours activity, maintaining a position approximately 1.36% below its 20-day moving average.

2026-09-18 23:52; UTC

Grab Holdings Ltd is trading lower in after-market hours, reaching its lowest price of the day and remaining significantly below its 20-day moving average.

2026-09-18 23:52; UTC

Correlated Moves

Jabil Inc is advancing in after-market trading, reflecting a significant rise since Friday's close and aligning with gains in the iShares Dynamic Equity Active ETF.

2026-09-18 23:52; UTC

Generac Holdings Inc is seeing a modest increase in after-market trading, aligning with broader market trends despite stagnation in U.S. industrial production data for August.

2026-09-18 23:51; UTC

Pacific Biosciences of California Inc declined during after-market trading, moving lower since Friday's close and currently below its 20-day moving average.

2026-09-18 23:51; UTC

Ribbon Communications Inc is declining in after-market trading, moving lower since Friday's close and trading well below its 20-day moving average.

2026-09-18 23:51; UTC

Amphenol Corp is gaining in after-market trading, reaching a notable high since Friday's close, despite remaining below its 20-day moving average.

2026-09-18 23:51; UTC

Lincoln National Corp is trading modestly higher in after-market hours, influenced by broader market gains amid ongoing geopolitical tensions and mixed economic data.

2026-09-18 23:51; UTC

Kyndryl Holdings Inc is moving higher in after-market trading, supported by broader market trends, despite stagnation in U.S. industrial production data for August.

2026-09-18 23:51; UTC

Correlated Moves

Microchip Technology Inc. is trading modestly lower in after-market hours, following a decline from earlier gains amid a broader downturn in the semiconductor sector.

2026-09-18 23:51; UTC

Correlated Moves

Southern Copper Corp is trading modestly lower in after-market hours, continuing a trend observed throughout the day, amid stable performance from the NYLIM FTSE ETF.

2026-09-18 23:51; UTC

EHang Holdings Ltd shows notable strength in after-market trading, advancing significantly from earlier lows despite remaining near the lower end of its one-month trading range.

2026-09-18 23:51; UTC

Cleveland-Cliffs Inc declined in after-market trading but remains above its 20-day moving average and near the upper end of its one-month range.

2026-09-18 23:51; UTC

Charter Communications Inc is rising in after-market trading, reaching its highest cumulative return since Friday's close, reversing a trend of recent declines.

2026-09-18 23:51; UTC

Event

Paychex Inc is trading higher in after-market hours ahead of its Q1 FY2027 earnings report, with EPS estimated at $1.32 and revenue at $1.6 billion.

2026-09-18 23:51; UTC

Devon Energy Corp's shares are modestly higher during after-market hours, currently positioned around the middle of their one-month trading range.

2026-09-18 23:51; UTC

Correlated Moves

Pfizer Inc is trading lower in after-market hours, reflecting a decline since Friday's close, influenced by Bristol-Myers Squibb's recent performance.

2026-09-18 23:51; UTC

American Electric Power Company Inc is trading modestly higher in after-market hours, recovering from earlier lows but remains below its 20-day moving average.

2026-09-18 23:51; UTC

Tractor Supply Co is seeing a modest increase in after-market trading, recovering from an earlier dip amid stagnation in U.S. industrial production.

2026-09-18 23:51; UTC

Kinder Morgan Inc is declining in after-market trading, having reached its lowest point of the day after fluctuating sharply during the session.

2026-09-18 23:46; UTC

Lamb Weston Holdings Inc is trading modestly higher in after-market hours, recovering from a low point shortly after the market closed.

2026-09-18 23:46; UTC

BRC Group Holdings Inc is trading modestly higher in after-market hours, despite a notable decline from earlier gains during the session.

2026-09-18 23:46; UTC

Tripadvisor Inc's stock advanced in after-market trading, fluctuating between a low of 0.06% and a high of 1.19% since Friday's close.

2026-09-18 23:46; UTC

Correlated Moves

Portland General Electric Co is trading modestly higher in after-market hours, reflecting broader gains in the Electric Utilities sector alongside Alliant Energy Corp.

2026-09-18 23:46; UTC

Viavi Solutions Inc is seeing modest gains in after-market trading, recovering from earlier fluctuations that pulled the stock back from a session high.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

103.25% į viršų

12 mėnesių prognozė

Vidutinis 5 USD 103.25%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.